Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
9 Feb 24
6-K
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
17 Jan 24
6-K
Publication of a transparency notification received from Fortress Investment Group LLC
21 Dec 23
6-K
Current report (foreign)
18 Dec 23
6-K
Celyad announces management change
4 Dec 23
6-K
Current report (foreign)
4 Dec 23
6-K
Celyad Oncology reports third quarter 2023 financial
24 Nov 23
6-K
Publication of a transparency notification received from
21 Nov 23
6-K
Current report (foreign)
21 Nov 23
6-K
Information on the Total Number of Voting Rights and Total Number of shares with single voting rights
15 Nov 23
6-K
Current report (foreign)
27 Oct 23
6-K
Celyad Oncology Announces the Termination of Its American Depository
26 Sep 23
6-K
Current report (foreign)
22 Sep 23
6-K
Publication of a rectified transparency notification received from
18 Sep 23
6-K
Current report (foreign)
13 Sep 23
6-K
Publication of a transparency notification received
11 Sep 23
6-K
Current report (foreign)
6 Sep 23
6-K
Celyad Oncology Reports First Half 2023 Financial
5 Sep 23
6-K
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
25 Aug 23
25-NSE
Exchange delisting
10 Jul 23
6-K
Celyad Oncology announces receipt of Nasdaq delisting notice
15 May 23
6-K
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
5 May 23
6-K
Celyad Oncology Announces Intent to
5 May 23
6-K
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
24 Apr 23
6-K
Celyad Oncology announces receipt of Nasdaq notice
5 Apr 23
6-K
Current report (foreign)
4 Apr 23
6-K
Current report (foreign)
24 Mar 23
6-K
Celyad Oncology reports full year 2022 financial results
23 Mar 23
20-F
2022 FY
Annual report (foreign)
23 Mar 23
6-K
Celyad Oncology announces non-cash impairment
15 Mar 23
6-K
Current report (foreign)
8 Mar 23
6-K
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
3 Feb 23
6-K
Current report (foreign)
21 Dec 22
6-K
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
10 Nov 22
6-K
Celyad Oncology Provides Strategic Update
12 Oct 22
6-K
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
20 Sep 22
6-K
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
5 Aug 22
6-K
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
1 Aug 22
6-K
Celyad Oncology Announces Leadership Updates
24 Jun 22
6-K
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
6 May 22
Latest ownership filings